Blueprint Medicines (NASDAQ:BPMC) reported Q4 EPS of ($2.65), $0.02 worse than the analyst estimate of ($2.63). Revenue for the quarter came in at $38.78 million versus the consensus estimate of $34.16 million.
Blueprint Medicines (NASDAQ:BPMC) reported Q4 EPS of ($2.65), $0.02 worse than the analyst estimate of ($2.63). Revenue for the quarter came in at $38.78 million versus the consensus estimate of $34.16 million.